Pemetrexed single agent chemotherapy in previously treated patients with locally advanced or metastatic non-small cell lung cancer

por Russo, Francesca, Bearz, Alessandra, Pampaloni, Gianni
Publicado 2008

Immune checkpoint inhibitors and response analysis: a tough challenge. A case report

por Bearz, Alessandra, Perin, Tiziana, Cancian, Luca, Berto, Eleonora, Sartor, Ivana, Tirelli, Umberto
Publicado 2016

Metronomic Chemotherapy: Anti-Tumor Pathways and Combination with Immune Checkpoint Inhibitors

por Muraro, Elena, Vinante, Lorenzo, Fratta, Elisabetta, Bearz, Alessandra, Höfler, Daniela, Steffan, Agostino, Baboci, Lorena
Publicado 2023

NSCLC as the Paradigm of Precision Medicine at Its Finest: The Rise of New Druggable Molecular Targets for Advanced Disease

por Michelotti, Anna, de Scordilli, Marco, Bertoli, Elisa, De Carlo, Elisa, Del Conte, Alessandro, Bearz, Alessandra
Publicado 2022

Targeted Therapy and Immunotherapy in Early-Stage Non-Small Cell Lung Cancer: Current Evidence and Ongoing Trials

por de Scordilli, Marco, Michelotti, Anna, Bertoli, Elisa, De Carlo, Elisa, Del Conte, Alessandro, Bearz, Alessandra
Publicado 2022

Therapeutical Options in ROS1—Rearranged Advanced Non Small Cell Lung Cancer

por Stanzione, Brigida, Del Conte, Alessandro, Bertoli, Elisa, De Carlo, Elisa, Revelant, Alberto, Spina, Michele, Bearz, Alessandra
Publicado 2023

Activity of crizotinib over choroidal metastases in Non-Small-Cell Lung Cancer (NSCLC)-ALK rearranged: a case report

por Bearz, Alessandra, Santarossa, Sandra, Manfrè, Antonio, Beltrame, Giorgio, Urbani, Martina, Sartor, Ivana, Da Ros, Valentina, Tirelli, Umberto
Publicado 2014

Brain Metastases Management in Oncogene-Addicted Non-Small Cell Lung Cancer in the Targeted Therapies Era

por De Carlo, Elisa, Bertoli, Elisa, Del Conte, Alessandro, Stanzione, Brigida, Berto, Eleonora, Revelant, Alberto, Spina, Michele, Bearz, Alessandra
Publicado 2022

Bone Metastasis and Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer (NSCLC): Microenvironment and Possible Clinical Implications

por Del Conte, Alessandro, De Carlo, Elisa, Bertoli, Elisa, Stanzione, Brigida, Revelant, Alberto, Bertola, Manuela, Spina, Michele, Bearz, Alessandra
Publicado 2022

Acquired Resistance to Osimertinib in EGFR-Mutated Non-Small Cell Lung Cancer: How Do We Overcome It?

por Bertoli, Elisa, De Carlo, Elisa, Del Conte, Alessandro, Stanzione, Brigida, Revelant, Alberto, Fassetta, Kelly, Spina, Michele, Bearz, Alessandra
Publicado 2022

Liquid Biopsy in NSCLC: An Investigation with Multiple Clinical Implications

por Bertoli, Elisa, De Carlo, Elisa, Basile, Debora, Zara, Diego, Stanzione, Brigida, Schiappacassi, Monica, Del Conte, Alessandro, Spina, Michele, Bearz, Alessandra
Publicado 2023

Sharing Experience with Anaplastic Lymphoma Kinase Tyrosine Kinase Inhibitors in Lung Cancer: An Italian Expert Panel Discussion

por Gridelli, Cesare, Tiseo, Marcello, Cortinovis, Diego Luigi, Migliorino, Maria Rita, Barbieri, Vito, Bironzo, Paolo, Bearz, Alessandra, Attili, Ilaria, de Marinis, Filippo
Publicado 2023

The Change in Paradigm for NSCLC Patients with EML4–ALK Translocation

por Bearz, Alessandra, De Carlo, Elisa, Del Conte, Alessandro, Spina, Michele, Da Ros, Valentina, Bertoli, Elisa, Revelant, Alberto, Stanzione, Brigida, Tirelli, Umberto
Publicado 2022

Concurrent chemoradiotherapy with tomotherapy in locally advanced non-small cell lung cancer: a phase i, docetaxel dose-escalation study, with hypofractionated radiation regimen

por Bearz, Alessandra, Minatel, Emilio, Rumeileh, Imad Abu, Borsatti, Eugenio, Talamini, Renato, Franchin, Giovanni, Gobitti, Carlo, Del Conte, Alessandro, Trovò, Marco, Baresic, Tanja
Publicado 2013

Outcomes of ALK positive lung cancer patients treated with crizotinib or second-generation ALK inhibitor: a monoinstitutional experience

por De Carlo, Elisa, Del Savio, Maria Chiara, Polesel, Jerry, Da Ros, Valentina, Berto, Eleonora, Santarossa, Sandra, Chimienti, Emanuela, Fratino, Lucia, Bearz, Alessandra
Publicado 2018

Therapeutic decision based on molecular detection of resistance mechanism in an ALK-rearranged lung cancer patient: a case report

por De Carlo, Elisa, Schiappacassi, Monica, Urbani, Martina, Doliana, Roberto, Baldassarre, Gustavo, Da Ros, Valentina, Santarossa, Sandra, Chimienti, Emanuela, Berto, Eleonora, Fratino, Lucia, Bearz, Alessandra
Publicado 2018

Re-challenge with pemetrexed in advanced mesothelioma: a multi-institutional experience

por Bearz, Alessandra, Talamini, Renato, Rossoni, Gilda, Santo, Antonio, de Pangher, Vincenzo, Fasola, Gianpiero, Rosetti, Francesco, Favaretto, Adolfo, Gregorc, Vanesa, Berretta, Massimiliano, Santarossa, Sandra, Berto, Eleonora, Tirelli, Umberto
Publicado 2012

Patient-Centered Cancer Care Programs in Italy: Benchmarking Global Patient Education Initiatives

por Truccolo, Ivana, Cipolat Mis, Chiara, Cervo, Silvia, Dal Maso, Luigino, Bongiovanni, Marilena, Bearz, Alessandra, Sartor, Ivana, Baldo, Paolo, Ferrarin, Emanuela, Fratino, Lucia, Mascarin, Maurizio, Roncadin, Mario, Annunziata, Maria Antonietta, Muzzatti, Barbara, De Paoli, Paolo
Publicado 2015

Post Hoc Analysis of Lorlatinib Intracranial Efficacy and Safety in Patients With ALK-Positive Advanced Non–Small-Cell Lung Cancer From the Phase III CROWN Study

por Solomon, Benjamin J., Bauer, Todd M., Ignatius Ou, Sai-Hong, Liu, Geoffrey, Hayashi, Hidetoshi, Bearz, Alessandra, Penkov, Konstantin, Wu, Yi-Long, Arrieta, Oscar, Jassem, Jacek, Calella, Anna M., Peltz, Gerson, Polli, Anna, Thurm, Holger, Mok, Tony
Publicado 2022